Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Australia Biotech + Invest 2020
25 slides from Neuroscientific Biopharmaceuticals's conference presentation, Oct 28, 2020
Slide 1: ASX Announcement: NeuroScientific to present at Australia Biotech + Invest 2020
For personal use only ASX ANNOUNCEMENT NEUROSCIENFITIC BIOPHARMACEUTICALS TO PRESENT AT AUSTRALIA BIOTECH + INVEST 2020 Perth, Australia; 28 October 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB (“NeuroScientific” or ”the Company”), a drug development company working with novel peptide-based
Slide 2: Novel Drug Therapies for Neurodegenerative Conditions
NOVEL DRUG THERAPIES FOR For personal use only NEURODEGENERATIVE CONDITIONS Australia Biotech Invest & Partnering 2020 Matt Liddelow, MPharm CEO & Managing Director ml@neuroscientific.com
Slide 3: Disclaimer
DISCLAIMER The purpose of the presentation is to provide an update of the business of For personal use only NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Slide 4: NeuroScientific Biopharmaceuticals Ltd
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) is developing peptide-based compounds that prevent neurodegeneration and stimulate neuroregeneration NEUROLOGY Targeted Alzheimer’s disease, Multiple peptides sclerosis, spinal cord injury
Slide 5: Partner / Investment Opportunity
PARTNER / INVESTMENT OPPORTUNITY For personal use only EmtinB is modelled on human metallothionein (MT-II) – well known pro survival NOVEL LEAD and regenerative protein COMPOUND First in-class therapeutic for neurodegenerative conditions Inhibits cell death (apoptosis), induces regeneration, m
Slide 6: EmtinB: LRP-1 Agonist That Promotes Neuronal Survival & Regeneration
EMTINB: LRP-1 AGONIST THAT PROMOTES NEURONAL SURVIVAL & REGENERATION For personal use only Binding activity Intracellular signalling ERK H H Lys Neuronal differentiation Lys OH P13K/Akt Neuronal survival H Lys Axonal regeneration Metallothionein-II H Neuronal plasticity EmtinB LRP-1 CREB M
Slide 7: Pipeline in a Product
EMTINB – PIPELINE IN A PRODUCT For personal use only INDICATION RESEARCH IND-ENABLING PHASE I PHASE 2 Alzheimer’s disease NEUROLOGY Multiple sclerosis Glaucoma OPHTHALMOLOGY Optic nerve atrophy Multiple EXPLORATORY indications 6
Slide 8: Neurology
For personal use only NEUROLOGY
Slide 9: Neurodegenerative Conditions Significantly Contribute to Global Burden of Disease
NEURODEGENERATIVE CONDITIONS SIGNIFICANTLY CONTRIBUTE TO GLOBAL BURDEN OF DISEASE For personal use only Neurodegeneration involves the progressive loss of neurons, the building blocks of the nervous system DEMENTIA & ALZHEIMER’S DISEASE MULTIPLE SCLEROSIS 50M people globally have dementia 2.5M globa
Slide 10: Promotes Neuronal Survival
EMTINB PROMOTES NEURONAL SURVIVAL Increases in vitro survival of damaged neurons from different regions of CNS For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: ALZHEIMER’S MODEL 10 9
Slide 11: Promotes Neuronal Regeneration
EMTINB PROMOTES NEURONAL REGENERATION Increases in vitro axonal regeneration in neurons from different regions of CNS For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: INJURY MODEL SPINAL CORD: INJURY MODEL 11 10
Slide 12: Promotes Remyelination in Multiple Sclerosis Model
EMTINB PROMOTES REMYELINATION IN MULTIPLE SCLEROSIS MODEL For personal use only Myelination: Increased number of oligodendrocytes MULTIPLE SCLEROSIS MODEL EmtinB, A2B5+ 875% Oligodendrocytes are support cells that create the EmtinB, MAG+ 607% myelin sheath that insulate axons; demyelination result
Slide 13: Slowed Cognitive Decline in Alzheimer's Model
EMTINB SLOWED COGNITIVE DECLINE IN ALZHEIMERS MODEL Significantly slowed progression of AD in gold standard mouse model (APPswe/PS1) For personal use only AD MOUSE MODEL Cognition: treatment for 48 days EmtinB 70% +7 ALZHEIMER’S ANIMAL MODEL Control 38% +5 Slowed progression of Alzheimer’s disease
Slide 14: Ophthalmology
For personal use only OPHTHALAMOLOGY
Slide 15: >5% of Global Population Suffer Vision Loss Due to Damaged Optic Nerve
>5% OF GLOBAL POPULATION SUFFER VISION LOSS DUE TO DAMAGED OPTIC NERVE For personal use only Optic nerve transmits visual information from the eye to the brain and is composed of 1.7 million nerve fibres GLAUCOMA OPTIC NEURITIS 76M global prevalence 10M global prevalence 2nd leading cause of blindne
Slide 16: Regenerating the Optic Nerve
REGENERATING THE OPTIC NERVE For personal use only No Treatment cut RAT TRANSECTION MODEL EmtinB precursor compound (MT-II): Stimulated regeneration of the optic nerve by up to 1000um Treatment (>250% vs non-treated) Axonal regeneration was evident well beyond the transection site 15
Slide 17: Ocular Tissue Penetration
EMTINB OCULAR TISSUE PENETRATION Intravitreal delivery demonstrated penetration of the retina and optic nerve head with no cytoxicity For personal use only Retina, 6-hours Optic nerve head, 6-hours OCULAR TISSUE PENETRATION IN RABBITS Significant concentrations of EmtinB (fluoro-labelled) detected
Slide 18: EmtinB Is Neuroprotective in Glaucoma
EMTINB IS NEUROPROTECTIVE IN GLAUCOMA Demonstrated neuroprotection in pig model of IOP glaucoma For personal use only GLAUCOMA PIG MODEL Increased intraocular pressure pig model is the closest % increase experiment to replicate severe human glaucoma pathology; positive results in this model indica
Slide 19: EmtinB Is Neuroprotective in Glaucoma
EMTINB IS NEUROPROTECTIVE IN GLAUCOMA Demonstrated neuroprotection in pig model of IOP glaucoma NFHp Non-treatment NFHp EmtinB For personal use only GLAUCOMA PIG MODEL Disruption of cytoskeleton proteins and neurofilaments in neuronal tissue are used as markers for axonal damage Tubulin Non-treatm
Slide 20: Financial Metrics & Milestones
For personal use only FINANCIAL METRICS & MILESTONES
Slide 21: Financial Metrics & Milestones
FINANCIAL METRICS & MILESTONES For personal use only FINANCIALS Completed IPO listing on the ASX July 2018 (ASX: NSB) >AUS$10 million capital raised since 2016 Currently funded through to completion of Phase 1 safety and tolerability ASX code NSB MILESTONES Shares on issue 78.58M Q4 2020 – C
Slide 22: Development Plan
EMTINB DEVELOPMENT PLAN For personal use only 2020 2021 2022 Ph1 ocular safety Q1 2021 Completion of Completion of ocular IND- neurology IND- Ph1 neurology Ph2 Alzheimer’s enabling studies enabling studies safety Ph2 ocular study study Q4 2020 Q1 2021 Q2 2021 Q1 2022 Q2 2022 21
Slide 23: Leadership Team
LEADERSHIP TEAM For personal use only , MBA Co-founder of ResApp Health 15 years experience Founding director of 20 years’ experience in Ltd (ASX.RAP), Imugene Ltd commercialising medical Actinogen Medical corporate advisory and (ASX:IMU) and Oncosil Ltd devices and pharmaceuticals (ASX:ACW) an adva
Slide 24: Summary Overview
SUMMARY OVERVIEW NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD (ASX: NSB) For personal use only • Drug development company with an advanced preclinical lead drug candidate called EmtinB; funded through to completion of Phase I in primary treatment indication • EmtinB targets LRP-1 expressed on the outside
Slide 25: For More Information
FOR MORE INFORMATION: For personal use only Matt Liddelow CEO & Managing Director ml@neuroscientific.com www.neuroscientific.com
NeuroScientific Biopharmaceuticals — Australia Biotech + Invest 2020 on 6ix